Abstract
BackgroundPL is approved for treating RG at 8 mg IV every 2 wks. Phase 1 testing suggested that 8 mg IV every 3 wks might also be effective. We have...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
